Stockscreener 앱 받기
1.5046
2.90%
-0.0454
전일 마감가:
$1.55
열려 있는:
$1.56
하루 거래량:
179.27K
Relative Volume:
0.30
시가총액:
$40.55M
수익:
$1.05M
순이익/손실:
$-48.82M
주가수익비율:
-0.8222
EPS:
-1.83
순현금흐름:
$-47.49M
1주 성능:
+15.77%
1개월 성능:
+16.67%
6개월 성능:
-19.95%
1년 성능:
-83.20%
1일 변동 폭
$1.4709
$1.6193
1주일 범위
$1.30
$1.64
52주 변동 폭
$1.06
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
명칭
Actinium Pharmaceuticals Inc
전화
646-767-3870
주소
275 Madison Avenue, 7th Floor, New York, NY
ATNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.50 | 40.55M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.43 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.99 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.49 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.35 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.20 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-02-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 개시 | B. Riley Securities | Buy |
| 2020-11-05 | 개시 | Alliance Global Partners | Buy |
| 2017-12-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-14 | 개시 | Maxim Group | Buy |
| 2016-08-25 | 개시 | ROTH Capital | Buy |
| 2016-02-29 | 개시 | H.C. Wainwright | Buy |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2014-10-01 | 개시 | MLV & Co | Buy |
| 2014-07-22 | 개시 | Canaccord Genuity | Buy |
모두보기
Actinium Pharmaceuticals Inc 주식(ATNM)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ... - Bluefield Daily Telegraph
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders - PR Newswire
JPMorgan Chase & Co. Acquires 110,141 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - GuruFocus
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. - GlobeNewswire
Actinium Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationATNM - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to - Bluefield Daily Telegraph
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation - Kilgore News Herald
Actinium Pharmaceuticals Inc’s results are impressive - uspostnews.com
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM) - PR Newswire
The Attractiveness of Investing In Actinium Pharmaceuticals Inc (ATNM) is Growing - knoxdaily.com
Actinium Pharmaceuticals Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Market Watch Highlights: Actinium Pharmaceuticals Inc (ATNM) Ends on an Downturn Note at 1.30 - DWinneX
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - PR Newswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium - GlobeNewswire
Actinium Pharma (ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models - StreetInsider
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting - Yahoo Finance
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Rese - PR Newswire
May 27, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ATNM - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire
Hematopoietic Stem Cell Transplantation Market to Reach New - openPR.com
ROSEN, A LEADING LAW FIRM, Encourages Actinium - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in - Bluefield Daily Telegraph
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for InvestorsContact Levi & Korsinsky - Morningstar
Investors who lost money on Actinium Pharmaceuticals, Inc. (ATNM) should contact Levi & ... - Bluefield Daily Telegraph
Investors who lost money on Actinium Pharmaceuticals, Inc. - GlobeNewswire
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class ActionATNM - marketscreener.com
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Join Class Action Suit Seeking Recovery - Bluefield Daily Telegraph
Actinium Pharmaceuticals Inc (ATNM Stock: A Sea of Opportunity - investchronicle.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire
Examining Actinium Pharmaceuticals Inc (ATNM) more closely is necessary - uspostnews.com
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - StreetInsider
Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025ATNM - marketscreener.com
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
Actinium Pharmaceuticals, Inc. Class Action: Levi & - GlobeNewswire
Actinium Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Actinium Investors of - Bluefield Daily Telegraph
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM)May 27, 2025 Deadline to JoinContact The Gross Law Firm - marketscreener.com
Actinium Pharmaceuticals Inc (ATNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):